Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)

ConclusionThis study showed the overall efficacy of luseogliflozin compared with DPP-4is over the mid/long term, regardless of BMI or age. The results suggest the importance of assessing multiple aspects regarding the effects of diabetes management.Trial Registration NumberjRCTs031180241.

http://link.springer.com/10.1007/s13300-023-01438-w

Source: Diabetes Therapy - July 6, 2023 Category: Endocrinology Source Type: research